French Regulatory Authority Gives Green Signal To Phio Pharma's Melanoma Trial

The French National Agency for the Safety of Medicines and Health Products has signed off Phio Pharmaceuticals Corp's (NASDAQ:PHIO) clinical trial with its lead product candidate, PH-762 in melanoma.

• The Company expects to dose the first patient in Q1 of 2022.
•  PH-762 activates immune cells to recognize better and kill cancer cells. It reduces the expression of PD-1, a clinically validated target for immunotherapy. 
• Related: Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation.
• PD-1 is expressed by T cells and prevents them from killing other cells, including cancer cells. Therefore, reducing PD-1 expression can reduce the ability of cancer cells to evade T cell detection and killing.
• The Company's first clinical trial with PH-762 will be a Phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma. 
• The study features a dose escalation of PH-762 monotherapy.
• Price Action: PHIO shares are trading 12.60% higher at $1.07 during the market session on the last check Tuesday.